论文部分内容阅读
异名 CBDCA,NSC-241240,JM-8,Paraplatin 化学名顺-二氨络-1,1-环丁烷二羧酸铂(Ⅱ) 药效分类抗癌药开发单位 (美)Johnson-Matthey 上市厂商 (英)Bristol Myers 1986年 4月上市文献 Proc AACR 1982,23∶129;癌化学疗法 1985,12(5):1137 药理本品是顺氯氨铂类抗癌药,其活性与顺氯氨铂相当,生化性质与顺氯氨铂类似,活性谱也类似,但毒性明显较低。它是一个烷化剂,主要是引起DNA的链间及链内交联,破坏DNA分子,阻止其螺旋解链。药物动力学本品口服无效,须静注。人静注本品后,其剂量与血浆中总铂以及可超
Synonyms CBDCA, NSC-241240, JM-8, Paraplatin Chemical Name cis-diammine -1,1-cyclobutane dicarboxylate Platinum (Ⅱ) Pharmacodynamic classification Anti-cancer drug development unit Manufacturer Bristol Myers April 1986 Listed Proc AACR 1982,23: 129; Cancer Chemotherapy 1985,12 (5): 1137 Pharmacology This product is a cisplatin-based anticancer drug whose activity is comparable to that of cis-chlorin The platinum is comparable in its biochemical properties to cisplatin, and its activity profile is similar but its toxicity is significantly lower. It is an alkylating agent, mainly caused by cross-linking of chains and chains within DNA, destroying DNA molecules and preventing their helices from melting. Pharmacokinetics This product is ineffective oral, intravenous injection. After intravenous injection of this product, its dose and plasma total platinum can be super